Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With DupilumabFrancesco Leo(University of Turin), M. Ortoncelli(University of Turin)International Journal of DermatologyJanuary 13, 202610.1111/ijd.70260Cited by 0SaveCiteExport RISWatch citationsRelated PapersLow-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients|Haematologica|2007|175